Hopefully, this will drive policy changes, lower prices, and expand access, while also marking an important shift: seeing obesity as a disease that deserves proactive, evidence-based treatment. While semaglutide is the most prominent of them all, dulaglutide and liraglutide, as well as the dual GLP-1/GIP agonist GIP plays a similar role to GLP-1 tirzepatide, present in Lillys Mounjaro and Zepbound, also join the list as therapeutic alternatives. Even biosimilars, which are drugs that are highly similar to biologics with regard to their quality, safety, and efficacy, were listed
This one matters a lot for weight loss, especially the kind thats been stubbornly resistant to diet changes
Heres a breakdown of the lowest monthly self-pay prices per drug, according to the telehealth companys website: Foundayo pill: From $149 per month Mounjaro: $1,899 per month Ozempic: From $199 per month Wegovy pill: From $149 per month Wegovy pen: From $199 per month Zepbound vial: From $299 per month Zepbound KwikPen: From $299 per month Interested patients can check their membership eligibility on the platform
The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp() somatotropinomas
So yeah, it was kind of almost like a specialization looking for something to treat
